Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.
Select Content Type
Clinical Guidelines
Authored By
Vassy, Jason L , Gaziano, J Michael , Green, Robert C , Ferguson, Ryan E , Advani, Sanjay , Miller, Stephen J , Chun, Sojeong , Hage, Anthony K , Seo, Soo-Ji , Majahalme, Nilla , MacMullen, Lauren , Zimolzak, Andrew J , Brunette, Charles A
Interests
Cardiology
Internal/Family Medicine
Book Detail
Publisher
American Medical Association
volume
3
ISSN
2574-3805 ; Electronic
Actions
Download in App
Event Data
{"article_title":"Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.","author":"Vassy, Jason L , Gaziano, J Michael , Green, Robert C , Ferguson, Ryan E , Advani, Sanjay , Miller, Stephen J , Chun, Sojeong , Hage, Anthony K , Seo, Soo-Ji , Majahalme, Nilla , MacMullen, Lauren , Zimolzak, Andrew J , Brunette, Charles A","journal_title":"JAMA network open","issn":"2574-3805 ; Electronic","isbn":"","publication_date":"20201201","volume":"3","issue":"12","first_page":"e2027092","page_count":"","accession_number":"33270123","doi":"10.1001\/jamanetworkopen.2020.27092","publisher":"American Medical Association","doctype":"Journal Article","subjects":"Pediatrics","interest_area":["Cardiology"," Internal\/Family Medicine"],"abstract":"Nonadherence to statin guidelines is common. The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. The unintended harms of using pharmacogenetic information to guide pharmacotherapy remain a concern for some stakeholders.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=33270123&authtype=shib&custid=ns346513"}
Nonadherence to statin guidelines is common. The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. The unintended harms of using pharmacogenetic information to guide pharmacotherapy remain a concern for some stakeholders.
